Meropenem Ldp-Laboratorios Torlan

Meropenem, the active ingredient in Meropenem Ldp-Laboratorios Torlan, is a carbapenem antibiotic presented as a sterile powder for intravenous infusion. It is used to treat severe bacterial infections in hospitalized patients, including intra‑abdominal, urinary, pulmonary, skin and soft‑tissue infections, as well as febrile neutropenia. GNH USA supplies Meropenem Ldp-Laboratorios Torlan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious infections that require intravenous therapy. - Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in patients with perforated viscera or postoperative peritonitis. - Complicated urinary tract infections: achieves microbiological clearance in resistant Gram‑negative uropathogens. - Nosocomial pneumonia: improves outcomes in ventilator‑associated or hospital‑acquired pneumonia caused by multidrug‑resistant organisms. - Severe skin and soft‑tissue infections: resolves cellulitis, necrotizing fasciitis, and other deep infections when other agents fail. - Febrile neutropenia: offers rapid bactericidal activity in immunocompromised patients with fever of unknown origin.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Diarrhea: mild to moderate loose stools, often self‑limiting. - Nausea or vomiting: gastrointestinal discomfort during or after infusion. - Rash: transient erythematous skin eruptions. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated colitis presenting with watery diarrhea. - Hemolytic anemia: rare immune‑mediated destruction of red blood cells.

Use meropenem only under medical supervision, considering patient‑specific factors and infection severity. - Renal function: adjust dose in patients with impaired clearance to avoid accumulation. - History of seizures: monitor closely, as the drug can lower seizure threshold. - Allergies: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk; data are limited. - Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic effects. Store at below 25°C: keep in the original container, protect from moisture and light, and discard after the expiry date.

Meropenem may affect or be affected by several co‑administered agents.

Major Interactions (Avoid): - Valproic acid: meropenem can markedly reduce serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides, vancomycin): combined use may exacerbate renal impairment; monitor renal function. - Anticoagulants (e.g., warfarin): occasional alterations in INR have been reported; check coagulation parameters. - Other β‑lactam antibiotics: overlapping spectra may increase risk of additive toxicity; assess necessity of combination therapy.